Loading stock data…
AMPH
$20.16+0.77 (+3.97%)
After Hours$20.16+0.00 (+0.00%)· Last close Jun 9
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Amphastar Pharmaceuticals, Inc. in the Healthcare sector is trading at $20.16. Wall Street consensus targets $22.83 (6 analysts), implying a +13.3% move over the next 12 months. The stock is currently 36% below its 52-week high of $31.26, remaining 17.4% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 71 is overbought against a weak tape. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +13.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 71 against a weak tape — risk of pullback
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$20.16
Potential Downside
0%
Whystock Fair Value$20.16
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus6 analysts
Hold
Mean target$22.83+13.3%
Range$19.00 – $30.00
Fundamentals
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
10.24%
Volume
Today's trading volume
496,066
Recent News
Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Drag
Amphastar Pharmaceuticals (NASDAQ:AMPH) executives told investors at the Jefferies Healthcare Conference that the company is maintaining expectations for mid- to high-single-digit revenue growth in 2026, supported by a new generic launch, Primatene Mist growth and selected API sales from its China b
Amphastar Pharmaceuticals, Inc. (AMPH) Price Target Cut to $21 At Piper Sandler Amid Pipeline Uncertainty
We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is one of the most undervalued pharma stocks. TheFly reported on May 11 that Piper Sandler reduced its price target on AMPH from $25 to $21 while maintaining a Neutral stance on the stock following the […]
3 Stocks Under $50 with Open Questions
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.
Why Wells Fargo Lowered Amphastar Pharmaceuticals, Inc. (AMPH) Price Target to $19
We recently compiled a list of the 8 Best Small Cap Pharma Stocks to Buy Right Now. Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is among the best pharmaceutical stocks on this list. TheFly reported on May 13 that Wells Fargo downgraded AMPH to Equal Weight from Overweight, with the price objective reduced to $19 from $30 in a […]
Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Lower Today
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) fell 2.8% in the morning session after Wells Fargo downgraded the company's stock to 'Equalweight' from 'Overweight' and significantly lowered its price target.